To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.
April 16-20, 2016 | New Orleans | Annual AACR meeting
Xentech is pleased to announce its participation to the prestigious American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans in April 16-20, 2016. Visit us at booth #1053 And Meet our scientists at the poster sessions. Poster # 2923 : Functional evaluation of interferon/STAT1 pathway activation in response to […]
Contract Research Organization
XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....